中国现代神经疾病杂志 ›› 2021, Vol. 21 ›› Issue (4): 289-295. doi: 10.3969/j.issn.1672-6731.2021.04.010

• 神经病理与人脑组织库建设 • 上一篇    下一篇

2 成人晚发型丙酸血症分子病理学分析:附一例报告并文献复习

薛秀云, 董亚茹, 王珺, 由凤秋, 狄政莉, 刘志勤   

  1. 710003 西安交通大学医学院附属西安市中心医院神经内科
  • 收稿日期:2021-04-15 出版日期:2021-04-25 发布日期:2021-04-27
  • 通讯作者: 刘志勤,Email:docterqing@163.com
  • 基金资助:

    陕西省西安市“科技”+行动计划——医学研究项目[项目编号:2019115113YX006SF039(3)]

Molecular pathology report of late-onset propionic acidemia in adults: one case report and literature review

XUE Xiu-yun, DONG Ya-ru, WANG Jun, YOU Feng-qiu, DI Zheng-li, LIU Zhi-qin   

  1. Department of Neurology, Xi'an Central Hospital, Xi'an Jiaotong University School of Medicine, Xi'an 710003, Shaanxi, China
  • Received:2021-04-15 Online:2021-04-25 Published:2021-04-27
  • Supported by:

    This study was supported by Xi'an Science and Technology plus Action Plan Medical Research Project [No. 2019115113YX006SF039 (3)].

摘要:

目的 首次报道1例国内PCCB基因突变致成人晚发型丙酸血症患者,总结其临床和分子病理学特点。方法与结果 男性患者,18岁,临床主要表现为急性发病的双侧基底节区对称性损伤导致的代谢性脑病伴不自主运动。干血斑串联质谱(MS/MS)法显示丙酰肉碱(C3)为10.37 μmol/L,丙酰肉碱/乙酰肉碱(C3/C2)比值为0.69;尿液气相色谱-质谱(GC/MS)法显示尿液3-羟基丙酸为18 μmol/L,甲基枸橼酸为12.70 μmol/L。基因检测显示,患者存在PCCB基因外显子10 c.1087T > C(p.Ser363Pro)纯合突变,其父母存在PCCB基因外显子10 c.1087T > C(p.Ser363Pro)杂合突变,符合家系共分离现象,该突变位点符合疑似致病性变异。最终分子病理诊断为晚发型丙酸血症。经限制蛋白饮食、大剂量左卡尼汀、降氨治疗后症状明显改善,复查干血斑(MS/MS法)和尿液(GC/MS法)有机酸测定,丙酸和尿液3-羟基丙酸显著下降。结论 PCCB基因外显子10 c.1087T > C(p.Ser363Pro)为罕见的疑似致病性变异,干血斑(MS/MS法)和尿液(GC/MS法)有机酸检测联合全外显子组测序在晚发型丙酸血症的诊断中具有重要应用价值。

关键词: 丙酸血症, 基因, 突变, 质谱分析法, 病理学, 分子

Abstract:

Objective To report the first case of adult late-onset propionic acidemia (PA) caused by PCCB gene mutation in China, and summary the clinical and molecular pathological characteristics of patients with late-onset propionic acidemia. Methods and Results The clinical manisfestions of an eighteen-year-old male patient were acute onset of symmetrical injury at bilateral basal ganglia which induced metabolic encephalopathy with involuntury movement. Tandem mass spectrometry (MS/MS) test results of dried blood spots indicated that propionyl carnitine (C3) was 10.37 μmol/L, and the ratio of propionyl carnitine to acetyl carnitine (C3/C2) was 0.69. Gas chromatography-mass spectrometry (GC/MS) test results indicated urine 3-hydroxypropionic acid was 18 μmol/L, methyl citrate level was 12.70 μmol/L. The gene results detected a homozygous pathogenic mutation (exon 10: c. 1087T > C, p. Ser363Pro) in the PCCB gene. His parents had a heterozygous mutation in PCCB gene exon 10 c.1087T > C (p.Ser363Pro), which was consistent with the phenomenon of family co-segregation, and the mutation site was consistent with a suspected pathogenic variant. The final molecular pathological diagnosis was late-onset propionic acidemia. Following the protein restriction diet, high-dose L-carnitine injection, and ammonia-lowering treatment, the dried blood spots propionic acid level and the urine 3-hydroxypropionic acid level decreased significantly. Conclusions The mutation exon c.1087T > C (p.Ser363Pro) is a rare and highly suspected pathogenic mutation of PCCB gene. MS/MS and GC/MS detection combined with whole exome sequencing technology is very important in the diagnosis of late-onset propionic acidemia.

Key words: Propionic acidemia, Genes, Mutation, Mass spectrometry, Pathology, molecular